Black Hawk Acquisition (BKHA) vs IN8bio (INAB)
Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.
Summary
IN8bio is the larger company by market cap ($8.2 million vs $7.7 million), about 1.1 times the size.
Summary generated from market data by MetaCap's automated system. Methodology
Relative performance
Percent change in share price from the first common trading day shown; excludes dividends.
Head-to-head
| Metric | BKHA | INAB |
|---|---|---|
| Share price | $1.85 | $0.758 |
| Market cap | $7.68M | $8.19M |
| 1-day change | -71.45% | -1.86% |
| YTD return | — | -67.61% |
| 1-year return | — | -55.41% |
| 5-year return | — | -99.63% |
| P/E ratio (TTM) | 5.61 | — |
| EPS (TTM) | $0.33 | $-1.00 |
| Dividend yield | 0.00% | 0.00% |
| Annual dividend | $0.00 | $0.00 |
| Net income (latest FY) | $1.33M | $-19.44M |
| 52-week high | $23.00 | $2.73 |
| 52-week low | $1.75 | $0.724 |
| Distance from 52-week high | -91.96% | -72.23% |
| Analyst consensus | — | none |
| Avg. price target upside | — | +823.48% |
| Average volume | 101.40K | 120.61K |
| Shares outstanding | 4.15M | 10.81M |
| Employees | — | 18 |
| Sector | Health Care | Health Care |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Biotechnology: Biological Products (No Diagnostic Substances) |
Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.
About Black Hawk Acquisition
BKHA stock →Black Hawk Acquisition Corporation is a blank check company focuses on effecting a merger, share exchange, asset acquisition, share purchase, reorganization, or similar business combination with one or more businesses or entities. The company was incorporated in 2023 and is based in Danville, California.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances)
About IN8bio
INAB stock →IN8bio, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of gamma-delta T cell product candidates for the treatment of cancer and autoimmune diseases. Its lead product candidates include INB-400, which is in Phase 2 clinical trial to treat newly diagnosed glioblastoma (GBM); INB-200, a genetically modified autologous gamma-delta T cell product candidate that is in Phase I clinical trial for the treatment of GBM; and INB-100, an allogeneic product candidate, which is in Phase I clinical trial to treat patients with hematologic malignancies undergoing hematopoietic stem cell transplantation.
Health Care · Biotechnology: Biological Products (No Diagnostic Substances) · 18 employees
BKHA vs INAB FAQ
Which is bigger, Black Hawk Acquisition or IN8bio?
IN8bio (INAB) is larger, with a market capitalization of $8.19M compared with $7.68M for Black Hawk Acquisition (BKHA).
Are Black Hawk Acquisition and IN8bio in the same industry?
Yes. Both are classified in the Biotechnology: Biological Products (No Diagnostic Substances) industry within the Health Care sector.